Madrigal logo.jpg
Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer
September 11, 2023 07:00 ET | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal logo.jpg
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
August 08, 2023 08:00 ET | Madrigal Pharmaceuticals, Inc.
Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug AdministrationNASH disease education and market development activities expand to support potential first-to-market launch in...
A Call for Help from
A Call for Help from Physician Specialists on the Frontline Treating MASLD/MASH
July 18, 2023 09:29 ET | Spherix Global Insights
Exton, Pennsylvania, July 18, 2023 (GLOBE NEWSWIRE) -- Data from the Centers for Disease Control & Prevention (CDC) suggests just over seventy percent of American adults are overweight,...
Madrigal logo.jpg
Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
July 17, 2023 08:00 ET | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
CytoSorbents New Logo - 2021.png
CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease
July 11, 2023 07:00 ET | CytoSorbents
PRINCETON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
MicrosoftTeams-image (5).png
Non-alcoholic Steatohepatitis Therapeutics Market to Grow at a CAGR of 13.6% during the 2022 to 2031 Forecast Period: TMR Study
July 07, 2023 07:00 ET | Transparency Market Research
Wilmington, Delaware, United States, July 07, 2023 (GLOBE NEWSWIRE) -- The global non-alcoholic steatohepatitis therapeutics market stood at US$ 10.1 billion in 2021 and the global non-alcoholic...
Madrigal logo.jpg
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
June 30, 2023 08:00 ET | Madrigal Pharmaceuticals, Inc.
Madrigal expects to complete full submission of the New Drug Application in July 2023 CONSHOHOCKEN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a...
Madrigal logo.jpg
Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
June 22, 2023 03:30 ET | Madrigal Pharmaceuticals, Inc.
First scientific presentation of detailed MAESTRO-NASH results confirms achievement of primary endpoints across multiple patient subgroupsNoninvasive imaging and biomarker data support findings on...
Growth in Patient an
Growth in Patient and Medical Community Engagement in NASH Community Persists Despite Recent Regulatory Disappointment
June 08, 2023 07:19 ET | Global Liver Institute
Washington, D.C., June 08, 2023 (GLOBE NEWSWIRE) -- Today is International NASH Day, a time where healthcare experts and community members around the globe step up and raise awareness of the most...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023
June 07, 2023 09:00 ET | Sagimet Biosciences Inc.
SAN MATEO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways,...